Rescop Opens Offices in UK and Australia
Rescop )Regulatory System Compliance Partners) has opened new offices in the UK and Australia.
Rescop (Regulatory System Compliance Partners) has opened new offices in the UK and Australia. This expansion follows the opening of branches in Belgium and the US last year.
“The move was required to accommodate both our current and future growth in EU and the Asia Pacific area, as we continue to expand our team of Life Sciences and software development experts to meet the increasing demand for our consulting services and software products.”
The company was found in 2005 by Piet Vervoort and Björn Aalbers. Its headquarters is in Den Bosch, The Netherlands, and it now has eight offices. It supplies GxP compliance software and services, and assists in the following areas: system life cycle management; commissioning, qualification and validation; change management; IT Delivery and Support; and training
Read the release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
